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Abstract
Aim: Use of tele-health programs and wearable sensors that allow patients to monitor their own vital signs have been expanded in response to COVID-
19. We aimed to explore the utility of patient-held data during presentation as medical emergencies.
Methods: We undertook a systematic scoping review of two groups of studies: studies using non-invasive vital sign monitoring in patients with chronic
diseases aimed at preventing unscheduled reviews in primary care, hospitalization or emergency department visits and studies using vital sign
measurements from wearable sensors for decision making by clinicians on presentation of these patients as emergencies. Only studies that described a
comparator or control group were included. Studies limited to inpatient use of devices were excluded.
Results: The initial search resulted in 896 references for screening, nine more studies were identified through searches of references. 26 studies fulfilled
inclusion and exclusion criteria and were further analyzed. The majority of studies were from telehealth programs of patients with congestive heart failure
or Chronic Obstructive Pulmonary Disease. There was limited evidence that patient held data is currently used to risk-stratify the admission or discharge
process for medical emergencies. Studies that showed impact on mortality or hospital admission rates measured vital signs at least daily. We identified
no interventional study using commercially available sensors in watches or smart phones.
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Conclusions: Further research is needed to determine utility of patient held monitoring devices to guide management of acute medical emergencies at
the patients’ home, on presentation to hospital and after discharge back to the community.
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Introduction
The COVID-19 pandemic has resulted in an increase in the number of
virtual wards1 that are monitoring patients in their own home to detect
deterioration and the need for hospital admission. In traditional
practice the decision about the need of an individual to require
admission to a hospital relies on the assessment of patients’
symptoms, signs, past-medical history, diagnosis and social support
at home24 and a judgment of the severity of illness based on an
estimated risk of deterioration in the subsequent hours and days.5
Abnormalities of vital signs are quantified by comparison with
‘normal’ measurements of healthy individuals during periods of
physiological stability. Within these individuals the ‘normal’ measure-
ments vary and are influenced by genetic determinants, age, sex,
body composition, medications and physical condition. There is an
association between the magnitude of change from a physiological
normal range, the number of vital signs affected by the disease state
and the frequency of adverse events.6,7 Abnormality can be scored
with generic tools that can be applied to the majority of patients such as
the National Early Warning Score (NEWS).8 However these scores
can under- or overestimate risk in individual patients.9
In patients with chronic conditions such as chronic heart failure
(CHF) or chronic obstructive pulmonary disease (COPD)10 vital signs
are often not comparable to those of healthy individuals even during
times of stability. In order to assess the severity of illness of a patient
with chronically abnormal vital signs clinicians might compare
measurements on presentation to hospital with values derived from
previous clinical encounters such as outpatient clinic visits, primary
care attendances or records from previous hospital admissions but do
usually not know what the patient's measurements are in their own
living and working life. Patients with heart failure are likely to have
chronically low pulse pressure11 and patients with COPD often have a
higher heart rate, respiratory rate and lower oxygen saturations than
patients without this condition.12 Beyond this, physiological reserve
might also affect the degree of physiological abnormality in response
to a disease.13
Knowing the values of an individual patient's vital signs during a
period of relative wellness might therefore help clinicians to
understand trends14 and the degree of deviation from normal and
hence the severity of illness of a patient. Individual vital signs (e.g.,
heart rate, heart rhythm, oxygen saturation) can easily be measured
by smartwatches and mobile telephones. Smart monitoring devices
allow data to be captured and interpreted by apps; connection to the
internet allows data to be shared in real time with others. Currently, 49
83% of the population of European countries and 79% of the United
States use smartphones, and this number is rising.15
According to the Institute of Medicine, the quality of interventions
can be defined in six dimensions16: safety, effectiveness, patient-
centeredness, timeliness, efficiency, and equity. Applied to acute care
we would therefore hypothesizes that wearable monitors would need
to demonstrate
1. improvements in the way that risk is quantified and managed,
2. effectiveness in identifying a significant change in the physiologi-
cal status of a person earlier than current methods and in real time,
3. the ability of patients to review and manage their own risk
according to their preferences,
4. the capability to link into protocols that use the data to initiate more
timely treatment before catastrophic deterioration in the commu-
nity, and finally
5. the ability of more citizens to have access to high quality
monitoring of their health.
In this review we aimed to map the literature on how measure-
ments of vital signs taken by patients at home might inform decision-
making on presentation to hospital or other emergency services and
identify gaps for future research.
Methods
We performed a scoping review using Arksey and O’Malley's
methodology and Levac's conceptual extension.17,18 We followed
the five-step process proposed by O’Malley's:
1. Identification of the research question: The research question was
formulated through an iterative process after a cursory screening
of the literature. Consensus on the search terms, inclusion of
studies and themes for synthesis were achieved during confer-
ence calls between the authors. We identified two related topics for
examination:
a. Long-term monitoring: How has non-invasive vital sign
monitoring been used in patients with chronic diseases to
prevent unscheduled reviews in primary care, hospitalization or
emergency department (ED) visits?
b. Opportunistic utilization: How are vital sign measurements
from wearable sensors utilized by clinicians on presentation
to emergency services such as out-of-hours primary care
services, emergency departments or acute medical units?
Given that current wearable sensors are able to measure
vital signs and mobility both areas were included in the
search.
2. Identification of relevant studies was through relevant MESH
terms: “Telemedicine” and “Wearable Electronic Devices” and
“Smartphone” were combined with “Vital Signs” and “Mobility
Limitation”. The searches were conducted on MEDLINE,
EMBASE and the Cochrane Library. The search was limited to
studies published on or before March 31st 2020. The search terms
that were used in the literature review are present in the appendix.
The search was undertaken in March of 2020 with additional
searches undertaken in October 2020 and January 2021.
3. Selection of studies:
Inclusion criteria: Included were studies in adult patients that
used non-invasive devices to measure at least one vital sign and
tracked unscheduled visits to primary care, emergency
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department or admission to hospital in such patients. Only
interventional or observational studies with a comparator or
control group were included.
Exclusion criteria: pilot or feasibility studies, conference
presentations; vital sign recordings limited to inpatient settings,
and studies without information about the monitoring device.
Additional searches were undertaken against a representative
sample of leading brand names: a search for studies involving
Apple Watch resulted in two case studies,19,20 no studies of
wearables by Fitbit, Garmin, Jawbone, Pebble, Polar and
Samsung were found.
4. Charting the data: Data was extracted from each manuscript in
a standardized format including information about type of
study, setting, number of study subjects, clinical conditions
included, nature of the device, duration of follow up, outcome
measures, important patient characteristics and clinical
impact.
HM undertook the primary searches and JK, JA & CSP
undertook secondary searches and verified data and data
extraction from the primary searches. Incongruences were
discussed in online consensus meetings.
5. Collating, summarizing and reporting the results: Identified studies
were grouped according to methodological and clinical themes.
Results were reported in tables and summarized in the
manuscript. The final manuscript was circulated twice between
all authors to achieve consensus.
Results
The original search conducted in March 2020 yielded 896 potentially
relevant citations. After screening 94 citations met the inclusion
criteria based on title and abstract and the corresponding full text
articles were procured for review. After sight of the full text 26 articles
were included in the study (Fig. 1: Flow diagram). Adding ‘mobility
limitations’ to the search resulted in no additional studies. Two studies
used the same dataset with different outcome measures.21,22
Of the 26 studies fulfilling our inclusion criteria three originated
from the US,2123 five from the UK,2428 three from Spain,2931 three
from Italy3234 and one from Germany,35 Taiwan,36 Japan,37
Finland,38 Belgium,39 Holland,40 Australia,41 New Zealand42 and
Denmark.43 Three studies were multi-center trials from Europe.4446
24 studies were randomized controlled trials and 2 studies were
before and after comparisons.
Characteristics of the interventions are summarized in Table 1 and
measurements and clinical outcomes in Table 2.
Characteristics of monitoring devices
Specified devices included the SweetageTM wrist wearable device,32
IntelTM health telemonitoring device,21,22 Wrist Clinic wearable
deviceTM,46 Motiva systemTM,27,47 Honeywell Home MedTM28,25
and a Tanita device designed to measure body-composition.37
Fig. 1 – PRISMA flow diagram for the searches of the Scoping Review.
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Table 1 – Study characteristics.
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Table 2 – Vital signs measures, outcomes and significant results. Parameters: glucose measurement (G),
Abbreviations: rhythm (R), electro-cardio-gram (ECG), Impedance (I), peakflow (PF), questionnaires (Q), spirometry
(S), weight (W). Clinical impact: usual care (UC), TelemonitoringTM, risk ratio (RR), incidence rate ratio (IRR), odds
ratio (OR), hazard ratio (HR), confidence Interval (CI), emergency department (ED).
Author Study Year Weight HR BP SPO2 Temp Others Frequency of monitoring Outcomes measured Clinical Impact
Heart-failure
J. Cleland 2005 X X X R Twice daily HospitalizationMortality Reduction in one year mor-
tality [16% p=0.032]R
eduction in admission dura-
tion [4 days (95%CI 10
days to +2 days)]
Mortara 2009 X X X Q, ECG Weekly Hospitalization
Mortality
No difference in hospitaliza-
tion and mortality




Reduction in HF emergencies
[UC 81%, TM 36%, p=0.01]
No difference in hospitalisa-
tions or cost (p=0.3).
Domingo 2011 X X X Q Daily Hospitalization
Duration of admission
Reduction in admissions with
heart failure [67.8% 95%CI
58.277.4%, p=0.01]
Reduction in duration of ad-
missions with heart failure
[73.3% 95%CI 64.282.4%,
p=0.037]
Dendale 2011 X X X Daily HospitalizationMortality
Cost
Reduction in mortality [17.5%
in UC vs 5% in TM, p=0.012]
Reduction in heart failure
hospitalization [0.42 in UC vs
0.24 in TM, p= 0.056)
Reduction in days lost due to
death or hospitalisations [30.2
UC vs 13.1 TM, p=0.025]




Increase in cardiology outpa-
tient clinic visits [IRR 3.31
95%CI 2.155, p<0.001]
No effect on duration of ad-
mission [IRR 0.812 95%CI
0.521.2, p=0.351]
Kraai 2015 X X Q, ECG Daily HospitalizationMortality
Cost
Reduction in cardiac outpa-
tient [4 UC vs 2 TM, p<0.02]
No difference in mortality [HR
1.25 95%CI 0.53, p=0.62]
No effect on readmissions
with heart failure [28% in UC
vs 27% in TM, p=0.63]
Kotooka 2018 X X X Daily Hospitalization
Mortality
No difference in hospitaliza-
tion [HR 0.79 95%CI 0.47
1.32, p=0.37]
No difference in mortality [HR
0.8 95%CI 0.351.84,
p=0.614)
Koehler 2018 X X X X ECG Daily Hospitalization
Mortality
Reduction in days lost due to
unplanned cardiovascular
hospitalization and all-cause
mortality [Ratio of weighted
averages 0.8 95%CI 0.65
1.0, p= 0.046]
Palmieri 2011 X X X 3/week Hospitalization
mortality
Decrease in hospitalizations
[2.2 in UC vs 0.9 TM, p<0.01]
No difference in mortality
COPD




No difference in hospitaliza-
tion [17 in UC vs 8 in TM,
p>0.05]
No difference in duration of
admission [162 in UC vs 85 in
TM, p>0.05]
No difference in ED visits [11
in UC vs 6 in TM, p>0.05]




No difference in hospitalisa-
tions [HR 1.08 95% CI 0.8
1.45, p=0.63]
No difference in duration of
admission [1.05 95% CI 0.75
1.48, p=0.78]
Pedone 2013 X X X Every 3h Acute exacerbationsHospi-
talization
Duration of admission
No difference in hospitaliza-
tion [IRR 0.66 95%CI 0.21
1.86, p>0.05]
No difference in duration of
admission [6.9 in UC vs 9.7 in
TM, p 0.05]
(continued on next page)
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Table 2 (continued)
Author Study Year Weight HR BP SPO2 Temp Others Frequency of monitoring Outcomes measured Clinical Impact
McDowell 2015 X X X Q Daily Hospitalisations
GP & ED visits
Insignificant reduction in hos-
pitalisations [Mean difference
0.15 95%CI 0.22 to 0.53,
p= 0.4]
Reduction in ED visits [Mean
difference 0.19 95%CI 0.25
to 0.63, p=0.4]
Reduction in GP visits [Mean
difference 0.9 95%CI 0.11
to 1.91, p=0.07]
Chatwin 2017 X X X X Daily Heart rate and SPO2,







[0.32 in UC vs 0.63 in TM,
p= 0.026]
Increase in home visits [0.75
in UC vs 4 in TM, p<0.001]
No difference in GP visits
[5.17 in UC vs 5.75 in TM,
p= 0.57]







[33 UC vs 12 TM, p=0.015]R
eduction in emergency visits
[57 UC vs 20 TM, p=0.001]
Reduction in duration of ad-
mission [276 UC vs 105 TM,
p= 0.018]
Ringbæk 2015 X X X S,Q Pulse oximetry and weight
3/week (first 4 weeks),
then 1/week. Spirometry




No difference in hospitalisa-
tions[0.54 in UC vs 0.55 in TM,
p= 0.74]
No difference in duration of
admission [5.29 in UC vs 5.35
in TM, p=0.38]




Reduction in hospital read-
missions [0.68 in UC vs 0.23 in
TM, p=0.002]
Reduction in ER visits [0.91 in
UC vs.36 in TM, p=0.006]
Reduced probability of COPD
related readmission [HR 0.42,
95%CI 0.190.92, p=0.026)
Walker 2018 X X X X I (forced os-
cillation
technique)




tions [IRR 0.46 95%CI 0.24
0.87, p=0.017]
Reduction in duration of ad-
mission [4 UC vs 1 TM,
p= 0.045]
Mixed population
Finkelstein1 2006 X X X S Twice weekly Mortality
Hospitalization
Nursing home admission
Reduction in hospital or
nursing admissions [42% UC
vs 17% TM, (p= 0.055) Re-
duction in mortality [26% in
UC, 20% in TM, p=0.74]




Reduction in hospital admis-
sions [OR 0.82 95%CI 0.7
0.97, p=0.017],
Reduction in mortality [0.54,
95%CI 0.390.75, p<0.001]
Reduction in emergency visits
[IRR 0.85, 95%CI 0.731,
p= 0.044]
Reduction in duration of ad-
mission [Mean difference
0.64 days, 95%CI 1.14 to
0.1, p=0.023]
Takahashi3 2012 X X G, S Daily ED visits
Hospitalization
Mortality
No difference in hospitalisa-
tions [45 UC vs 53 TM,
p= 0.2}.
No difference in emergency
visits [29 UC vs 36 TM, p=0.2]
Increased mortality [4 UC vs
15, p=0.008]




[RR 0.66, 95% CI 0.440.99,
p= 0.033]
Reduction in duration of ad-
mission [10.7 UC vs 9 TM,
p= 0.89)
Reduction in mortality [8 in UC
vs 3 in TM, p=0.31]
Upatising5 2015 X X X G Daily Total standardized cost:
inpatient, outpatient and ED
Insignificant reduction in total
health care cost by 33%
(p=0.068)
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Twenty three studies used standard medical devices and manual
data entry or modems to monitor the vital signs2128,30,31,3445,47
while two studies used a wearable electronic device for monitor-
ing.32,46 Details on characteristics of monitoring devices was missing
in one study.48
Information was transferred through a secure broadband internet
connection was in eleven studies21,22,24,26,27,31,3638,43,47 whilst
cellular communication devices were utilized in five stud-
ies32,35,39,40,46 and communication through a telephone line was
used in nine studies.23,25,28,30,34,41,42,44,45
Devices in four studies had built in transmission capability via the
internet: Two of these were wearable electronic devices (Sweet-
ageTM,32 WristclinicTM46); the other two utilized an Intel HealthTM
Telemonitoring device.21,22
Parameters measured
Twenty three studies evaluated tele-monitoring devices while two
studies,32,46 reported on the use of wearable electronic device: studies
involving telemonitoring utilized between one and five vital signs
(Table 2): Heart rate (n=11) and weight (n=14) were the most
commonly monitored vital sign in studies on heart failure (n=16)
whereas oxygen saturation (n=13) was most commonly monitored in
studies on COPD (n=13). Blood pressure was the most measured
variable among all the telemonitoring studies (n=20) followed by
weight (n=18), heart rate (n=17), oxygen saturation (n=17),
electrocardiogram (n=4), temperature (n=3) and spirometry (n=3)
(Table 2). Two studies used wearable wrist devices to measure heart
rate, temperature, blood pressure, pulse oximetry.32,46 Forced
Oscillation Technique,46 a non-invasive method that evaluates the
resistance and reactance of the respiratory system, was used in
COPD patients.
Telemetric measurements were taken at variable intervals:
once,38,43,45 twice23 or thrice weekly,33 once daily21,22,2428,30,31,35
37,3942,47 or twice daily.44 One study had variable monitoring
regime.43 In the two studies using wearable electronic device one
study monitored five times a day32 while the other monitored once
daily.46
Monitoring with patient questionnaires
Twelve out of 21 selected telemedicine studies utilized a subjective
assessment of patient's symptoms in the form of a questionnaire along
with the vital signs to anticipate worsening.2426,28,30,31,34,40,41,43,45,47
These questionnaires were completed digitally or were communicat-
ed verbally by telephone. Out of these twelve, four studies
demonstrated a reduction in number of hospitalisations or length of
stay.26,2931
Response to abnormal Vital signs
Responses to abnormal vital signs could be in real time/instantaneous
or scheduled/intermittent. Full details of the telemonitoring protocol
were available for all the studies (Table 1): Protocols in eight studies
involved the use of automatic computer algorithms for patient risk
assessment.30,31,36,39,40,4446 These algorithms were either based on
a pre-defined alarm limits for vital signs or a dynamic range based on
historical vital signs of the individual patient. Only patients with
measurements outside the alarm limits were reviewed by clinical staff.
Six of these studies30,31,36,39,44,46 demonstrated significant reduction
in hospitalization and mortality.
In 15 studies, all the data obtained from the patients was monitored
regularly by clinical staff, of these, three26,34,48 showed improved
clinical outcomes. Three studies combined both automated algo-
rithms and direct monitoring,24,27,35 of these one35 showed statistically
significant reduction in hospitalization.
Abnormal vital signs resulted in a number of interventions: lifestyle
and/or medication advice, medication review and adjustments, video
conferences, primary care referrals, home visits, secondary care
referrals and admissions to hospital (Table 1).
Diagnostic groups studied
Ten studies evaluated the impact of telemonitoring in CHF25,29,35,37
40,44,45,48 but wearable technology was not evaluated. Improvement
in chosen clinical outcomes for chronic heart failure patients was
associated with the frequency of vital sign monitoring: Five of eight
studies that measured vital signs at least daily29,35,39,44 vs none that
used weekly38,45 monitoring. Weight,25,29,35,3740,44,45 heart
rate25,29,35,3739,44,45,48 and blood pressure25,29,35,3740,44,45,48 were
monitored in almost all the studies whereas oxygen saturation was
measured in only three25,35,48 of which two studies35,48 could
demonstrate reduced hospitalisations in the intervention group.
ECG was monitored in 4 studies35,40,44,45 out of which two studies
showed significant reduction in number of hospital admissions or
duration of admissions35,44 (Table 2).
Nine studies24,27,28,30,32,36,41,43,46 evaluated the impact of tele-
monitoring in COPD and two32,46 assessed the wearable wrist devices
Table 2 (continued)
Author Study Year Weight HR BP SPO2 Temp Others Frequency of monitoring Outcomes measured Clinical Impact
Vitacca6 2009 X Q Weekly (but variable) Hospitalisations
GP & ED Visits
Reduction in hospitalisations
per month [0.22 UC vs 0.14
TM, p<0.01]
Reduction in GP visits [0.22
UC vs 0.07 TM, p<0.002]
No difference in emergency
room admissions [0.1 UC vs
0.07 TM, p>0.05]
Kenealy7 2015 X X X X Daily Hospitalisations, ED visits, No difference in hospitalisa-
tions (p=0.15) or ED visits
(p=0.9)
Patient populations examined in the studies with mixed population: 1. chronic wound care, HF and COPD, 2. diabetes, HF, COPD, 3. heart disease, COPD,
diabetes, stroke, dementia, 4. HF, chronic lung disease, 5. cancer, CHF, COPD, dementia, diabetes, renal insufficiency, stroke, 6. COPD, restrictive lung diseases,
amyotrophic lateral sclerosis, neuromuscular disorders, HF, 7. CHF, COPD and diabetes.
R E S U S C I T A T I O N P L U S 6 ( 2 0 2 1 ) 1 0 0 1 1 6 9
SweetageTM and Wrist clinicTM. In most of these studies patients were
monitored daily, and all measured oxygen saturation: one also
measured spirometry,43 one measured peak expiratory flow30 and
one study used Forced Oscillation Technique.46 Two out of the seven
telemonitoring studies30,36 showed significant reduction in hospital-
isations and emergency room visits while only one46 study using
wearable electronic devices could demonstrate improvement. Two of
the three studies which showed significant improvement used some
measure of lung function for monitoring30,46 (Table 2).
Seven studies2123,26,31,34,42 evaluated the impact of telemonitor-
ing on a general population with a variety of diseases such as COPD,
heart failure, diabetes, cancer, dementia, chronic wound care, renal
failure, chronic respiratory failure and stroke (Table 2). All studies
used conventional devices. Three26,31,34 showed significant reduction
in hospitalisations. The largest clinical trial in this group, with 2762
patients who were followed for a year, showed significant reduction in
hospital bed days.26 Patients with heart failure and COPD were
present in all the studies (Table 2).
Clinical outcome measures
Outcomes were compared in parallel groups between monitored and
unmonitored patients in 24 studies. The remaining two studies were
pre-post-intervention studies.47,48
Clinical outcomes in studies of telemonitoring included emergency
presentations to primary care, rate of hospital admissions, duration of
admission, time to hospital admission, healthcare cost and mortality
(Table 2). Four studies used a composite outcome of hospitalizations
and mortality.35,37,40,45 Clinical outcomes in studies of wearable
sensors included number of hospitalizations32 and disease exacer-
bations,32 time to admissions,46 re-hospitalizations46 and length of
stay.46
Interventions in 12 studies2428,30,32,34,35,37,42,46 were progres-
sively escalated (advice, medication adjustments, home visits,
referrals and admissions) based on the severity of vital sign
derangements and their symptoms; five of these studies26,30,34,35,46
demonstrated a statistically significant reduction in hospitalizations
and/or mortality. 132123,4345,47,31,36,3841 studies utilized a single
intervention regardless of severity (medical advice, medication review
or referral); five of these studies31,36,39,44,47 demonstrated statistically
significant reduction in hospitalization.
Significant reductions in either number of hospitalizations and/or
mortality in the monitored group occurred in only 11 out of 26 studies:
five in heart failure patients,29,35,39,44,48 three in COPD30,36,46 and
three in patients with multiple conditions.26,31,34
Discussion
Major findings
This review identified significant gaps in the existing literature. No
studies described the use of patient held data on admission to hospital
to support decision making about clinical care, admission, or
discharge. Vulnerable and high-risk patient groups were excluded
from some of the studies, yet these might have been the very patients
with most to gain from trend analysis of vital signs available on arrival
to hospital. Moreover, despite the availability of an accelerometer on
every smart phone, we found no study considered prior mobility for
triage decisions.
Limitations
This focused scoping review only examined manuscripts from peer-
reviewed journals and included only fully licenced (i.e., FDA or CE
marked) devices and no prototypes. We did not include trials that are
currently in progress and have not been reported yet. We are unsure
how many studies might have been reported outside of peer-reviewed
journals in lifestyle or consumer magazines. In most trials, vital signs
were recorded infrequently using conventional devices. Only two
studies used wearable devices that performed measurements as
frequently as every hour and transmitted this data directly to a remote
database. Therefore, impact of using continuous monitoring of vital
signs with wearable devices could not be appraised. The use of
wearables for clinical research might be currently limited by battery life
and might increase as battery technology advances.
Interpretation
Telemonitoring has been focused predominantly on patients with two
disease groups: COPD and heart failure. Almost all studies that
reported statistically significant results used measurements that were
performed at least once per day. We found no evidence of use in other
patient groups with common chronic physiological abnormalities such
as asthma, atrial fibrillation, glomerulonephritis, or liver cirrhosis.
Several studies did not include patients with cognitive impairments
and those with end-stage disease.
Consumer grade vital sign monitoring has been available for over
15 years and vital signs can be measured by patients even without
medical grade sensors.49 Anecdotal reports about the utility of
wearables to identify significant illness have been published,20,50 but
the Apple Watch series 3 linked to an external KardiaBand51,52 and
Apple Watch series 4 are the first consumer device that were licensed
as a medical device by the U.S. Food and Drug Administration (FDA)
for its ability to record an electro-cardiogram (ECG) to detect rhythm
abnormalities.53,54 Longitudinal monitoring of trends in heart rate have
predictive power but the clinical application is far from clear55,56 and
health-economic evaluations of the older generation of tele-medicine
devices might not be cost-efficient.57,58
Understanding of trends in vital signs is important for the whole
patient journey before, during and after assessment in an emergency
department59 or acute medical unit.60 Algorithms and Artificial
Intelligence may bring a new age of safety to healthcare. However,
machine learning requires large amounts of data that is current,
correct and complete, and the number of patients currently enrolled in
studies so far reported may not be sufficient. Wearables have also
been suggested as a tool for pre-hospital triage in major disasters61
and can be used to predict long term health outcomes: A review found
only eight studies predicting either long-term mortality or readmissions
to hospital.62 Given the large amount of devices sold the small number
of published studies still seems curious.
Clinical implications
It remains to be seen if the participation of patients in their own
monitoring is empowering and improves care or creates needless
anxiety as patients notice fluctuations on their vital signs that are within
the normal range. There are also real concerns around digital
inclusion of frail and elderly patients and about equitable access to
services for those with limited digital literacy. Although the need to
monitor patients remotely has been thrown into sharp focus by the
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COVID-19 pandemic,63,64 the impact of notifications generated by
automated systems on workload of already over-stretched clinical
teams in primary and secondary care requires further assessment.65
While intermittent and continuous vital sign monitoring has been a
backbone of safe care for patients admitted to hospital66 or in a clinical
prehospital setting,67 there is currently little literature is available on its
use in the community.
Conclusion
There are significant gaps in the peer reviewed literature with
important opportunities for future research and development. Despite
the possibilities of frequent and continuous measurement of vital
signs, most studies used conventional devices for home monitoring.
There is little evidence that vital signs recorded by patients are used for
decision making by clinicians at the hospital front door; this was true for
both consumer and medical devices. Only studies that performed
measurements at least once per day found measurable impact on
mortality and health-economic metrics. More studies are needed to
determine if home measured vitals can improve early detection, timely
management and holistic recovery of patients presenting to health
services with medical emergencies.
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